Beam Therapeutics analyst ratings
Beam Therapeutics analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
05/09/2022 | 250.22% | SVB Leerink | $118 → $121 | Maintains | Outperform |
04/28/2022 | 79.45% | Credit Suisse | → $62 | Initiates Coverage On | → Neutral |
01/10/2022 | 250.22% | SVB Leerink | $116 → $121 | Maintains | Outperform |
01/05/2022 | 276.27% | Guggenheim | → $130 | Initiates Coverage On | → Buy |
11/09/2021 | 235.75% | SVB Leerink | $117 → $116 | Maintains | Outperform |
10/19/2021 | 238.64% | SVB Leerink | → $117 | Initiates Coverage On | → Outperform |
09/10/2021 | 334.15% | B of A Securities | → $150 | Initiates Coverage On | → Buy |
06/29/2021 | 331.26% | Wedbush | $114 → $149 | Maintains | Outperform |
05/11/2021 | — | Redburn Partners | Initiates Coverage On | → Buy | |
05/04/2021 | 146.02% | RBC Capital | → $85 | Initiates Coverage On | → Sector Perform |
03/01/2021 | 160.49% | Barclays | $47 → $90 | Downgrades | Overweight → Equal-Weight |
02/16/2021 | 319.68% | Wells Fargo | → $145 | Initiates Coverage On | → Overweight |
01/29/2021 | 189.44% | JP Morgan | $38 → $100 | Downgrades | Overweight → Neutral |
01/06/2021 | 143.13% | Stifel | → $84 | Initiates Coverage On | → Hold |
08/05/2020 | -4.49% | William Blair | → $33 | Initiates Coverage On | → Outperform |
03/02/2020 | -7.38% | Wedbush | → $32 | Initiates Coverage On | → Outperform |
03/02/2020 | -7.38% | Barclays | → $32 | Initiates Coverage On | → Overweight |
03/02/2020 | -7.38% | Jefferies | → $32 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
05/09/2022 | 250.22% | SVB Leerink | $118 → $121 | 維護 | 跑贏大盤 |
04/28/2022 | 79.45% | 瑞士信貸 | → $62 | 開始承保 | →中性 |
01/10/2022 | 250.22% | SVB Leerink | $116 → $121 | 維護 | 跑贏大盤 |
01/05/2022 | 276.27% | 古根海姆 | → $130 | 開始承保 | →購買 |
11/09/2021 | 235.75% | SVB Leerink | $117 → $116 | 維護 | 跑贏大盤 |
10/19/2021 | 238.64% | SVB Leerink | → $117 | 開始承保 | →跑贏大盤 |
09/10/2021 | 334.15% | B of A證券 | → $150 | 開始承保 | →購買 |
06/29/2021 | 331.26% | 韋德布什 | $114 → $149 | 維護 | 跑贏大盤 |
05/11/2021 | — | Redburn合作伙伴 | 開始承保 | →購買 | |
05/04/2021 | 146.02% | 加拿大皇家銀行資本 | → $85 | 開始承保 | →行業表現 |
03/01/2021 | 160.49% | 巴克萊 | $47 → $90 | 評級下調 | 超重→等重 |
02/16/2021 | 319.68% | 富國銀行(Wells Fargo) | → $145 | 開始承保 | →超重 |
01/29/2021 | 189.44% | 摩根大通 | $38 → $100 | 評級下調 | 超重→中性 |
01/06/2021 | 143.13% | Stifel | → $84 | 開始承保 | →保留 |
08/05/2020 | -4.49% | 威廉·布萊爾 | → $33 | 開始承保 | →跑贏大盤 |
03/02/2020 | -7.38% | 韋德布什 | → $32 | 開始承保 | →跑贏大盤 |
03/02/2020 | -7.38% | 巴克萊 | → $32 | 開始承保 | →超重 |
03/02/2020 | -7.38% | 傑富瑞 | → $32 | 開始承保 | →購買 |
Beam Therapeutics Questions & Answers
BEAM治療學問答
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by SVB Leerink on May 9, 2022. The analyst firm set a price target for $121.00 expecting BEAM to rise to within 12 months (a possible 250.22% upside). 9 analyst firms have reported ratings in the last year.
BEAM治療公司(納斯達克代碼:BEAM)的最新目標價是由SVB Leerink於2022年5月9日報道的。這家分析公司將目標價定為121.00美元,預計BEAM將在12個月內上漲至250.22美元(可能上漲250.22%)。去年有9家分析公司公佈了評級。
The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by SVB Leerink, and Beam Therapeutics maintained their outperform rating.
比姆治療公司(納斯達克代碼:BEAM)的最新分析師評級由SVB Leerink提供,比姆治療公司維持其表現優於大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閲公共財務報表,與比姆治療公司的高管和客户交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。BEAM治療公司的上一次評級是在2022年5月9日提交的,所以你應該預計下一次評級將在2023年5月9日左右提供。
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $118.00 to $121.00. The current price Beam Therapeutics (BEAM) is trading at is $34.55, which is out of the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但最新的光束治療公司(BEAM)評級保持不變,目標價在118.00美元至121.00美元之間。BEAM目前的交易價格為34.55美元,超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。